Show simple item record

dc.contributor.authorMasmudi-Martín, M
dc.contributor.authorZhu, L
dc.contributor.authorSanchez-Navarro, M
dc.contributor.authorPriego, N
dc.contributor.authorCasanova-Acebes, M
dc.contributor.authorGiralt, E
dc.contributor.authorMasmudi-Martín, M.
dc.contributor.authorZhu, L.
dc.contributor.authorSanchez-Navarro, M.
dc.contributor.authorPriego, N.
dc.contributor.authorCasanova-Acebes, M.
dc.contributor.authorRuiz-Rodado, V
dc.contributor.authorGiralt, E.
dc.contributor.authorValiente, Manuel 
dc.date.accessioned2021-04-21T06:25:07Z
dc.date.available2021-04-21T06:25:07Z
dc.date.issued2021-02
dc.identifier.citationAdv Drug Deliv Rev.2021 Feb;169:79-99.es_ES
dc.identifier.issn0169-409Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/12709
dc.description.abstractBrain metastasis is emerging as a unique entity in oncology based on its particular biology and, consequently, the pharmacological approaches that should be considered. We discuss the current state of modelling this specific progression of cancer and how these experimental models have been used to test multiple pharmacologic strategies over the years. In spite of pre-clinical evidences demonstrating brain metastasis vulnerabilities, many clinical trials have excluded patients with brain metastasis. Fortunately, this trend is getting to an end given the increasing importance of secondary brain tumors in the clinic and a better knowledge of the underlying biology. We discuss emerging trends and unsolved issues that will shape how we will study experimental brain metastasis in the years to come.es_ES
dc.description.sponsorshipThe authors want to acknowledge the work of the many authors cited that have been used to write this review. Research in the Brain Metastasis Group is supported by MINECO (SAF2017-89643-R) (M.V.), Fundacio La Marato de TV3 (141) (M.V.), Melanoma Research Alliance (Bristol-Myers Squibb-Melanoma Research Alliance Young Investigator Award 2017 (498103)) (M.V.), Fundacion Ramon Areces (CIVP19S8163) (M.V.), Worldwide Cancer Research (19-0177) (M.V.), H2020-FETOPEN (828972) (M. V.), Cancer Research Institute (Clinic and Laboratory Integration Program CRI Award 2018 (54545)) (M.V.), AECC (Coordinated Translational Groups 2017 (GCTRA16015SEOA) (M.V.), LAB AECC 2019 (LABAE19002VALI) (M.V.)), ERC CoG (864759) (M.V.), AECC Postdoctoral Grant (POSTD19016PRIE) (N.P), La CaixaSevero Ochoa International PhD Program Fellowship (LCF/BQ/SO16/52270014) (L.Z.). M.V. is an EMBO YIP (4053). M.C-A is supported by the 2020 AACR-AstraZeneca Immuno-oncology Research Fellowship, Grant Number 20-40-12-CASA. CNIO is supported by the ISCIII, the Ministerio de Ciencia e Innovacion, and is a Severo Ochoa Center of Excellence (SEV-2015-0510).es_ES
dc.language.isoenges_ES
dc.type.hasVersionSMURes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectEXPERIMENTAL MODELSes_ES
dc.subjectPRECLINICAL THERAPYes_ES
dc.subjectBRAIN METASTASISes_ES
dc.subjectORGANOTROPISMes_ES
dc.subjectBBBes_ES
dc.subjectBTBes_ES
dc.subjectSMALL-MOLECULE DRUGSes_ES
dc.subjectNANOMEDICINESes_ES
dc.subjectIMMUNOTHERAPYes_ES
dc.titleBrain metastasis models: What should we aim to achieve better treatments?es_ES
dc.typepreprintes_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID33321154es_ES
dc.format.volume169es_ES
dc.format.page79-99es_ES
dc.identifier.doi10.1016/j.addr.2020.12.002es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España) 
dc.contributor.funderFundación La Marató TV3 
dc.contributor.funderBristol-Myers Squibb 
dc.contributor.funderFundación Ramón Areces 
dc.contributor.funderWorldwide Cancer Research 
dc.contributor.funderUnión Europea. Comisión Europea. H2020 
dc.contributor.funderCancer Research Institute (CRI). Clinic & Laboratory Integration Program (CLIP)
dc.contributor.funderAsociación Española Contra el Cáncer 
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC) 
dc.contributor.funderFundación La Caixa 
dc.contributor.funderAstraZeneca 
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) 
dc.description.peerreviewedNoes_ES
dc.identifier.e-issn1872-8294es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.addr.2020.12.002.es_ES
dc.identifier.journalAdvanced drug delivery reviewses_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Metástasis Cerebrales_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2017-89643-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/828972es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/141es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CIVP19S8163es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/GCTRA16015SEOAes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/LABAE19002VALIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/864759es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/POSTD19016PRIEes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/LCF/BQ/SO16/52270014es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/20-40-12-CASAes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SEV-2015-0510es_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional